Medicine
Cardamyst 70 mg/0.2 mL nasal spray
Cardamyst 70 mg/0.2 mL nasal spray is a prescription medicine containing Etripamil for nasal use, marketed by Milestone Pharmaceuticals, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Ambient
Store at 20°C to 25°C (68°F to 77°F), with excursions permitted from 15°C to…
Key facts
- Active ingredient (INN)
- Etripamil
- Brand
- Cardamyst
- Strength
- 70 mg/0.2 mL
- Dosage form
- Nasal spray
- Route
- Nasal
- Packs
- 2 containers
- Marketing authorisation holder
- Milestone Pharmaceuticals
- Manufacturer
- Milestone Pharmaceuticals
- Origin register
- US FDA, United States
- Storage
- Store at 20°C to 25°C (68°F to 77°F), with excursions permitted from 15°C to 30°C (59°F to 86°F).
- Cold chain
- Not required on record
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- HS code (indicative)
- 3004.90Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 5 January 2026
- Identifiers
- RxCUI 2730307, 2730313DailyMed set ID a92170b9-4f93-4b83-b2cd-cb85c52821cdNDC 83468-070Application NDA218571
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 2 container in 1 carton / 2 vial, single-dose in 1 container / .2 mL in 1 vial, single-dose | 83468-070-03 | Milestone Pharmaceuticals | 5 January 2026 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
| Register | Status | Source |
|---|---|---|
| US FDA | Listed, marketed | Source record for this pageChecked 12 November 2026 |
| US FDA | First approved 12 December 2025 | Drugs@FDA |
| EU (EMA) | Not recorded | — |
| India (CDSCO) | Not yet confirmed against CDSCO approval lists | — |
| United States | Registered | US FDA (NDC directory, openFDA)Checked 12 November 2026 |
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Clinical summary
Etripamil is a prescription medicine indicated for the conversion of acute symptomatic episodes of paroxysmal supraventricular tachycardia (PSVT) to sinus rhythm in adults. It is available as nasal spray. MedsAcross supplies Etripamil for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about EtripamilFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- Cardamyst prescribing information (Milestone Pharmaceuticals) · U.S. National Library of Medicine, DailyMed
Need Cardamyst 70 mg/0.2 mL nasal spray for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.